Information about Procarbazine
Liver safety of Procarbazine
Procarbazine therapy has been associated with serum enzyme elevations during therapy and with rare cases of idiosyncratic, clinically apparent acute liver injury.
Mechanism of action of Procarbazine
Procarbazine (proe kar' ba zeen) is a methylhydrazine derivative which is activated in the liver to highly reactive alkylating intermediates. These intermediates methylate DNA which causes inhibition of DNA, RNA and protein synthesis and cell death.
FDA approval information for Procarbazine
Procarbazine was approved for use in the United States in 1969 and it remains a commonly used agent in the treatment of Hodgkin’s and non-Hodgkin’s lymphomas and brain cancer. Procarbazine is rarely used alone, but is found in common cancer chemotherapeutic regimens such as MOPP (mechlorethamine, vincristine [oncovin], procarbazine and prednisone), COPP (cyclophosphamide, vincristine [oncovin], procarbazine and prednisone), and PCV (procarbazine, lomustine [CCNU], vincristine).
Dosage and administration for Procarbazine
Procarbazine is available as tablets of 50 mg generically and under the brand name Matulane. It is typically given in monthly or every other month cycles of 10 to 14 days in a dose of 100 mg per meter squared body surface area.
Side effects of Procarbazine
- Common side effects are alopecia, anoxia, nausea, vomiting, headache, peripheral neuropathy, and flu-like illness.